Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ragde

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
The Prostate|January 1, 1996
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicityB Tjoa, A Boynton, G Kenny, et al.
The Prostate|August 1, 1995
In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapyB Tjoa, S Erickson, R Barren, et al.
CA: a Cancer Journal for Clinicians|May 1, 1995
Brachytherapy for prostate cancerA T Porter, J C Blasko, P D Grimm, et al.
Cancer|July 18, 2000
Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-upH Ragde, L J Korb, A A Elgamal, et al.
The Urologic Clinics of North America|November 1, 1996
Should brachytherapy be considered a therapeutic option in localized prostate cancer?J C Blasko, H Ragde, R W Luse, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1997
Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancerB R Prestidge, D C Hoak, P D Grimm, et al.
Critical Reviews in Immunology|January 7, 1998
Dendritic cell-based immunotherapy of prostate cancerM L Salgaller, B A Tjoa, P A Lodge, et al.
Cancer|July 15, 1996
Current prognostic factors and their relevance to stagingR V Hutter, J E Montie, C Busch, et al.
Cancer|September 10, 1998
Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinomaH Ragde, A A Elgamal, P B Snow, et al.
Cancer|August 1, 1997
Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinomaH Ragde, J C Blasko, P D Grimm, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
The Prostate|January 1, 1996
Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicityB Tjoa, A Boynton, G Kenny, et al.
The Prostate|August 1, 1995
In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapyB Tjoa, S Erickson, R Barren, et al.
CA: a Cancer Journal for Clinicians|May 1, 1995
Brachytherapy for prostate cancerA T Porter, J C Blasko, P D Grimm, et al.
Cancer|July 18, 2000
Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-upH Ragde, L J Korb, A A Elgamal, et al.
The Urologic Clinics of North America|November 1, 1996
Should brachytherapy be considered a therapeutic option in localized prostate cancer?J C Blasko, H Ragde, R W Luse, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1997
Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancerB R Prestidge, D C Hoak, P D Grimm, et al.
Critical Reviews in Immunology|January 7, 1998
Dendritic cell-based immunotherapy of prostate cancerM L Salgaller, B A Tjoa, P A Lodge, et al.
Cancer|July 15, 1996
Current prognostic factors and their relevance to stagingR V Hutter, J E Montie, C Busch, et al.
Cancer|September 10, 1998
Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinomaH Ragde, A A Elgamal, P B Snow, et al.
Cancer|August 1, 1997
Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinomaH Ragde, J C Blasko, P D Grimm, et al.
Pageof 5